Amyotrophic lateral sclerosis (ALS), known as Lou Gehrig’s disease, is an incurable neurological disorder affecting motor neurons—nerve cells in the brain and spinal cord that control voluntary muscle movement and breathing.
University of North Carolina Lineberger Comprehensive Cancer Center researchers have developed a “two-in-one” molecule that can simultaneously turn off two notoriously difficult-to-target cancer-related genes, KRAS and MYC, as well as directly deliver drugs to tumors that express these genes. This advance holds special promise for treating cancers that have been historically challenging to treat.
Biomedical and genetic engineers at Duke University and the Albert Einstein College of Medicine have developed a technique that naturally increases the presence of a light-sensitive molecule throughout the body.
Heart attacks remain a leading cause of death and disability worldwide. The permanent loss of heart muscle cells—known as cardiomyocytes—and the heart’s limited regenerative capacity often lead to chronic heart failure. Current treatment strategies manage symptoms but do not repair the underlying damage.
In a first-of-its-kind clinical trial, UCLA scientists have shown it’s possible to reprogram a patient’s blood-forming stem cells to generate a continuous supply of functional T cells, the immune system’s most powerful cancer-killing agents.
Animals that hibernate are incredibly resilient. They can spend months without food or water, muscles refusing to atrophy, body temperature dropping to near freezing as their metabolism and brain activity slow to a crawl. When they emerge from hibernation, they recover from dangerous health changes similar to those seen in type 2 diabetes, Alzheimer’s disease, and stroke.
For nearly three decades, Mayo Clinic researcher Christopher Evans, Ph.D., has pushed to expand gene therapy beyond its original scope of fixing rare, single-gene defects. That has meant systematically advancing the field through laboratory experiments, pre-clinical studies and clinical trials.
Reliable and gentler control of cellular activity with light: Researchers at the Cluster of Excellence Multiscale Bioimaging (MBExC) and the Else Kröner Fresenius Center for Optogenetic Therapies (EKFZ OT) of the University Medical Center Göttingen (UMG) have developed a light-sensitive protein that can restore vision and hearing and regulate heart rhythm.
The test employs advanced RNA technology to identify biomarkers for colorectal cancer and advanced adenomas.
Simplified Process Aims to Boost Participation in Colorectal Cancer Screening and Improve Early Detection Rates